Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.10USD
25 Apr 2018
Change (% chg)

$-0.03 (-1.41%)
Prev Close
$2.13
Open
$2.12
Day's High
$2.14
Day's Low
$2.10
Volume
9,547
Avg. Vol
25,208
52-wk High
$2.71
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 1.93
Market Cap(Mil.): $65.04
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 29.65 32.31
EPS (TTM): -0.29 -- --
ROI: -33.21 13.36 12.97
ROE: -78.52 15.09 14.84

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

Mar 21 2018

BRIEF-Sophiris Bio Announces Complete Enrollment In Phase 2B Topsalysin Study

* SOPHIRIS BIO ANNOUNCES COMPLETE ENROLLMENT IN PHASE 2B TOPSALYSIN STUDY OF LOCALIZED PROSTATE CANCER Source text for Eikon: Further company coverage:

Dec 11 2017

BRIEF-Sophiris Bio posts Q3 loss per share $0.09

* Sophiris Bio reports third quarter financial results and key corporate highlights

Nov 09 2017

BRIEF-bluebird bio reports qtrly ‍loss per share $1.73​

* bluebird bio reports third quarter 2017 financial results and recent operational progress

Nov 01 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,565 -13.50
Pfizer Inc. (PFE.N) $36.68 -0.38
Merck & Co., Inc. (MRK.N) $59.63 -0.46
Sanofi SA (SASY.PA) €65.87 --
GlaxoSmithKline plc (GSK.L) 1,412.20 --
Eli Lilly And Co (LLY.N) $81.14 +1.05

Earnings vs. Estimates